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Abstract 
Electrochemical studies were performed with omeprazole, active metabolites and a bound enzyme 
model. The active metabolites, cyclic sulfenamide and sulfur radical entities, exhibited reduction 
potentials of - 0.3 V and - 0.2 V respectively. The value for the bound enzyme model was - 0.7 V and 
that for omeprazole was > - 1.4 V. The results lend credence to the hypothesis that electron transfer 
comprises part of the mode of action in addition to (H+/K+ J ATPase inhibition. 
INTRODUCTION 
Benzimidazole sulfoxides, such as omeprazole 1 (Fig. 1) are potent anti-ulcer 
agents [l-6]. The proposed mode of action involves inhibition of gastric acid 
secretion into the lumen of the stomach by blockage of (H+/K+) ATPase (proton 
pump) of the parietal cell. Omeprazole itself is not the actual inhibitor of the 
enzyme, but must be transformed into an “active principle” within the cell [1,3,51. 
Two of the most likely active substances are the thiophilic cyclic sulfenamide 2 
[l-5], and the radical 6 formed by loss of water and rearrangement [6]. Both 
materials are thought to inactivate the ATPase by binding via mercapto groups 
1561, e.g. formation of 3a from 2. We suggest that a prior or subsequent mecha- 
nism may entail electron-transfer (ET) processes (redox chemistry) [7] which might 
alter enzymatic reactions including proton pumping. The proposed active metabo- 
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Fig. 1. Structures of the compounds studied. 
lites contain potential ET functionalities (conjugated iminium [8-111 or odd 
electron species [12]). We have previously proposed a similar mode of action for 
the anticancer agents methotrexate and difluoromethylornithine [81 and for /3- 
lactam antibiotics [9-111. Conjugated iminium ions may play a role in proton 
pumping in the vision process via photo-induced intramolecular ET [13,14]. Appar- 
ently, the need for transformations such as 1 + 2 -+ 3a is not essential in vivo. 
Thus, Fischli et al. 1151 reported that salts structurally related to 3a protect rats 
against gastric ulceration. Quinolinium salts also inhibit (H+/K+) ATPase [16]. 
However, the need for binding to the enzyme may still be required. 
The aim of the current study was to investigate the electrochemical properties 
of omeprazole, and particularly the active agents, based on the hypothesis of 
catalytic ET participation in the mode of action. 
EXPERIMENTAL 
Omeprazole 1 was a gift from AB Hassle, Sweden. Timoprazole was prepared 
as reported [17] (MP, 148-150°C; literature MP, 150-154°C). Salt 2 (X = BFJ was 
synthesized by the method of Figala et al. [l] (MP, 151°C dec.; reported MP, 150°C 
dec. [41). The analogous ion generated from timoprazole could not be isolated; 
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Senn-Bilfinger et al. [4] have reported similar failure. The enzyme bound model 3b 
was prepared by literature methods [18]. Reaction of 2-chlorobenzimidazole with 
pyridine yielded 4, isolated as the perchlorate (MP, 230-232°C; literature MP, 
232-233°C [19]>. The ylide 5, prepared from 4 [19], gave an MP of 256-257°C dec. 
(reported MP, about 260°C dec). Radical species 6 resulted from the decomposi- 
tion of timoprazole in 0.1 M HCl at room temperature [6]. The supporting 
electrolyte, tetraethylammonium perchlorate (TEAP) (G.F. Smith Chemical Co.>, 
was used without further purification. Dimethylformamide (DMF) and acetoni- 
trile, both HPLC grade (Aldrich Chemical Co.), were used as obtained. Aqueous 
buffers, pH 5.1 (potassium hydrogen phthalate (KHP)) and pH 7.0 (phosphate), 
were prepared by standard methods [201. 
Cyclic voltammetry and normal pulse polarography were performed in the dark 
using a Princeton Applied Research Corporation (PARC) model 264A polaro- 
graphic analyzer connected to a PARC model 303A SMDE as previously reported 
t211. 
RESULTS AND DISCUSSION 
The reduction potential (more negative than - 1.4 V) (Table 1) of omeprazole 
would not be amenable to participation of ET reactions in vivo. However, since 1 is 
a prodrug [l], the value has little significance. Benzimidazole sulfoxides incapable 
of forming ions of type 2 show no anti-ulcer activity [l]. An irreversible reduction 
of - 0.36 V was observed for 2 (Table 1) in acetonitrile [51. The wave had an I&+ 
of 100 mV; the value is normally about 60 mV for a single electron transfer [ref. 
23, p. 213). Perhaps the width reflects the presence of two regio-isomers, lo-OCH, 
TABLE 1 
Reduction potentials of omeprazole and conjugated pyridinium ions a 
Compound CHsCN solvent DMF solvent H z0 solvent 
E, /V E DD/2 /mV G/V E D0/2/mV h/V 
:b - - 0.36 100 - >-1.4 - 0.30 105 - - 
:: - 0.75 49 c 160 7  - 0.74 48 150 6  - - 0.65 d, - 0.71 e 
5 - 1.02 75 - 0.96 50 -0.72 ’ 
a Substrate concentration 0.5 mM; [TEAR]= 0.1 M; potentials measured versus the standard calomel 
electrode (SCE) adjusted to the standard hydrogen electrode (SHE); scan rate, 0.1 V/s. 
b Electrochemistry in 0.1 M HCI was accompanied by severe adsorption at the Hg electrode, similar to 
aqueous omeprazole [22]. 
’ Single determination. 
d pH 5.1, adsorption peak at - 0.40 V. 
’ pH 7.0, adsorption peak at -0.47 V. 
f pH 7.0, adsorption peak at -0.49 V. 
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and 9-OCH,, which form in a 2: 1 ratio [1,4]. Calculation of simple Hiickel 
molecular orbitals [24] indicate that the major isomer has a slightly lower lying 
lowest unoccupied molecular orbital (LUMO) which may result in somewhat 
different reduction potentials for the two isomers. The first half-wave potentials 
for related aza-heteroaromatic compounds correlated well with the energies of the 
lowest vacant molecular orbitals calculated by Hiickel methods 1251. In DMF an E, 
of -0.30 V was obtained with an Epp,2 value of 105 mV. The material adsorbed 
strongly at the mercury electrode in pH 5.1 buffer. No further studies were 
performed. 
A model of the enzyme bound inhibitor is 3b [26,27]. The presence of pyri- 
dinium in the enzyme inhibitor complex is thought to be important [27]. Under our 
non-aqueous conditions, 3b reduced about 400 mV more negative than the cyclic 
sulfenamide with a peak width of 150 mV. The difference is probably due mainly 
to the decrease in coplanarity of the two heteroaromatic rings; salt 3 is relatively 
free to rotate about the C-N bond, whereas the additional bridge in 2 enforces a 
more coplanar arrangement 14,281. There is also a shift in the UV absorption 
maxima toward shorter wavelengths upon formation of 3b [29], indicating de- 
creased r overlap. Reports of other bridged biaryl systems reveal similar influ- 
ences of coplanarity on reduction potential and UV spectra [30-321. The reaction 
is probably due to the reduction of the pyridinium ring and not the disulfide 
linkage since diphenyl disulfide did not exhibit electron uptake prior to - 1.3 V in 
DMF. The reduction potential of 3 is slightly more negative than the value of - 0.6 
V which is believed to be the limit for in vivo functioning [33]. However, if binding 
to enzyme induces a more coplanar arrangement in 3, then El,* would become 
more positive. 
The effect of substituents is shown by comparison of salts 3b and 4. The 
potential of the inhibited enzyme model should be about 240 mV more negative 
than for 4; the alkyl group makes reduction more difficult by up to 80 mV [34], and 
incorporation of a methoxy substituent in position 4 of the pyridine ring in the 
N-phenylpyridinium ion decreases the reduction value by 0.03 V 1351. Table 1 
reveals a difference of 0.26 V, indicating similar rotation about the C-N bond in 
both salts. Related ions of the N-styrylpyridinium type reduce in the range from 
-0.6 to -0.7 V 1211. In the present study, increased conjugation favors greater 
ease of electron uptake. 
In order to gain a better understanding of the reduction process, normal pulse 
polarography was performed on ion 4 (E1,2 = -0.44 V> and the results are given 
in Table 2. Comparison of limiting currents for 4 (2.7 FA) with those for the 
N-benzylpyridinium ion (3.6 PA), a substance known to be reduced by one 
electron [36], indicate that the same number of electrons is being transferred. A 
one-electron transfer was also indicated by a value of 67 mV for a plot of E versus 
log[(Z, - Z)/Z]; the theoretical value is 59 mV (ref. 23, p. 136). 
The ylide of 2 may be generated by nucleophilic attack on the sulfur of cyclic 
sulfenamide with formation of benzimidazolide 111. The expected reduction value 
for the ylide should be even more negative than that of model 5 (E, = - 1 V 
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TABLE 2 
Normal pulse polarography of 4 and 5 a 
Compound h/,/V hi /PA E3,4 - b/4 
4 -0.44 2.7 57 
5 - 0.94 4.6 55 
a Substrate concentration 0.5 mM; [TEAP] = 0.1 M; DMF; potentials measured versus SCE adjusted to 
SHE. 
b Limiting currents for N-benzyl and N-methylpyridinium ions: 3.6 PA and 4.5 PA respectively. 
(Table 1)) because of substituent effects (cf. 3b and 4). Ylide 5 exhibited a 
drawn-out anodic peak between zero and +0.2 V in DMF. E, for this anodic 
process was +0.12 V, similar to that for the 1-methylpyridinium ion [361. These 
voltammetric features have been attributed to one-electron reduction to the 
pyridinyl radical, followed by rapid dimerization to the corresponding tetra- 
hydropyridine moiety and oxidation of the dimeric species back to the original ion. 
Pulse polarography was performed on 5 in DMF; an E1,2 of -0.94 V was 
observed (Table 2). The limiting current was 4.6 Z.& the N-methylpyridinium ion 
gave an Id of 4.5 Z.LA. A value of 55 mV was obtained for E3,4 - E,,4. 
Cyclic voltammetry in aqueous buffer solutions (Table 1) of 4 generated diffu- 
sion-controlled reduction peaks at -0.71 V at pH 7.0 and at -0.65 V at pH 5.1 
with absorption peaks at - 0.47 and - 0.40 V respectively. Examination of 5 at pH 
7.0 resulted in a voltammogram almost indistinguishable from that of 4. It is 
possible that 4 is generated from 5 under these conditions. A salt, e.g. 4, is formed 
from the ylide in aqueous acid [19]. 
The second active principle that may be involved in ET is the radical 6. The 
results of our electrochemical studies are given in Table 3; all processes were 
reversible. In DMF 6 reduced at -0.19 V. There was a slight increase in the 
separation of peaks as the scan rate increased, the average being that for a 
one-electron transfer (ref. 23, p. 213), with the ratio of the anodic to the cathodic 
peak currents equal to unity. Thus the reaction is chemically reversible, i.e. the 
radical is regenerated as the potential is reversed. A difference of 80 mV in E,,, 
was observed as the solvent was changed to acetonitrile, similar to that found for 2. 
Another electrochemical possibility for 6 is oxidation, which occurred at 0.54 V 
in both solvent systems. The separation of peaks is close to that for a one-electron 
process. However, as the scan rate decreased the ratio of the currents deviated 
substantially from unity, indicating that the cation is unstable and undergoes a 
chemical reaction subsequent to oxidation. The relationship of oxidation potential 
magnitude to feasibility of in vivo operation is discussed elsewhere [12]. 
Free radicals appear to be associated with the pathogenesis of gastric ulcers 
[37,381. Radical scavengers such as p-carotene provide cytoprotection [38]. Perhaps 
the bound drug 3a, 2 or the radical 6 may act as an electron sink in the protection 
mechanism, thus inhibiting the formation of harmful radicals. 
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TABLE 3 
Electrochemistry of 6 a 
Solvent Scan E 
rate/mV s-r 
En/V E1/2 /V PP/2 /mV Ipa /[PC 
DMF b 20 -0.21 -0.19 50 0.97 
50 - 0.21 -0.19 57 1.03 
100 -0.21 -0.19 63 1.05 
200 - 0.22 -0.19 72 1.1 
CH,CN b 20 - 0.30 - 0.27 55 0.74 
50 - 0.30 - 0.27 55 1.03 
100 -0.30 -0.27 60 1.03 
200 -0.31 - 0.27 75 1.1 
DMF ’ 50 0.57 0.54 70 1.92 
100 0.58 0.54 70 1.78 
200 0.59 0.54 80 1.47 
CH,CN ’ 50 0.56 0.54 50 1.13 
100 0.56 0.54 50 1.06 
200 0.56 0.54 50 1.02 
a [6]= 0.5 mM; [TEAP] = 0.1 M; scan rate, 100 mV/s; potentials measured versus SCE adjusted to 
SHE. 
b Reduction process, Epc values. 
’ Oxidation process, Epa values. 
In vitro studies with omeprazole and its analogs indicate that the bound drug 
can be displaced from the enzyme by the addition of thiols, which partially 
reactivated the enzyme 11,391. According to our theory, removal of the electron 
carrier, i.e. the conjugated pyridinium ion, from the enzyme would eliminate 
participation of ET at the binding site. The cationic nature of 3 restricts membrane 
permeability, preventing the active inhibitor from entering the cell cytosol where it 
could result in non-specific inhibition [40]. Omeprazole has also been shown to 
interact with the mixed function oxidase system in vitro and in vivo [41]. 
Hence omeprazole metabolites can be regarded as proton-channel blockers [42]. 
If ET is involved, then similarity exists to calcium-channel antagonists [43] and 
benzodiazepines [44,45], for which ET mechanisms have been proposed to account 
in part for the influence on ion channels. 
OTHER CONSIDERATIONS 
If the hypothetical framework is correct, then other anti-ulcer drugs might also 
function in a similar manner. An attractive possibility is the metallatrane category 
[46]. The anti-ulcer effect appears to be mediated by the anti-oxidant activity. 
Nitrofurans [471 and CL@) complexes [48l, which are known ET agents [7,491, also 
display anti-ulcer properties. SCH 28080 [50], which is readily protonated, would 
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be transformed in the gastric region to a highly conjugated pyrrolopyridinium 
moiety that might well be capable of involvement in ET. 
We have previously discussed the possible effects of in vivo binding on reduc- 
tion potential and reversibility [511. The ET approach has also been applied to 
various drugs, including fungicidalI521, anthelmintic [49] and antimycobacterial [71 
compounds. References to other xenobiotics studied (carcinogens, anticancer 
agents, amebicides, antimalarials and central nervous system affecters) are given 
elsewhere [49]. 
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